"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 1 | 3 |
| 1999 | 0 | 1 | 1 |
| 2002 | 4 | 2 | 6 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 3 | 3 |
| 2016 | 5 | 1 | 6 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 3 | 3 | 6 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Xpert MTB/RIF Ultra assay for pulmonary tuberculosis and rifampicin resistance in adults and adolescents. Cochrane Database Syst Rev. 2025 07 29; 7:CD009593.
-
Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children. Int J Tuberc Lung Dis. 2025 Jun 27; 29(7):312-317.
-
Fluoroquinolone Resistance in Drug-Resistant Tuberculosis, Kharkiv, Ukraine, 2019-2023. Emerg Infect Dis. 2025 Mar; 31(3):615-617.
-
Shifting tuberculosis dynamics in the EU/EEA: geographical and drug resistance trends among people of foreign origin, 2019 to 2023. Euro Surveill. 2025 Mar; 30(11).
-
Completion, Safety and Tolerability of Once-weekly Isoniazid and Rifapentine for Tuberculosis Infection by Children and Adolescents. Pediatr Infect Dis J. 2025 Feb 14; 44(8):755-758.
-
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 02; 9(2):100-111.
-
Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention. Int J Tuberc Lung Dis. 2025 02 01; 29(2):67-74.
-
Epidemiological, clinical, biochemical, and treatment characteristics of brucellosis cases in Turkey. J Infect Dev Ctries. 2024 Jul 29; 18(7):1066-1073.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response. Clin Microbiol Infect. 2024 Sep; 30(9):1207-1208.
-
Antistreptococcal treatment of psoriasis: a systematic review. Arch Dermatol Res. 2024 Jun 08; 316(7):363.